您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2019, Vol. 57 ›› Issue (7): 61-66.doi: 10.6040/j.issn.1671-7554.0.2019.698

• 临床医学 • 上一篇    

57例急性淋巴细胞白血病异基因造血干细胞移植后抗宿主病的发生及影响因素分析

孙菲菲,房孝生,姜玉杰,隋潇徽,刘新,王相华,李英,张凌岩,许洪志,王欣   

  1. 山东大学附属省立医院血液科, 山东 济南 250021
  • 发布日期:2022-09-27
  • 通讯作者: 王欣. E-mail:xinw@sdu.edu.cn
  • 基金资助:
    国家自然科学基金(81270598,81473486,81770210);山东省重大科技创新工程(2018CXGC1213);山东省重点研发计划(2017GSF1819,2016GSF201029);济南市科技发展计划(201705008)

Graft-versus-host disease secondary to allogeneic hematopoietic stem cell transplantation in 57 patients with acute lymphoblastic leukemia

SUN Feifei, FANG Xiaosheng, JIANG Yujie, SUI Xiaohui, LIU Xin, WANG Xianghua, LI Ying, ZHANG Lingyan, XU Hongzhi, WANG Xin   

  1. Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Published:2022-09-27

PDF (PC)

78

摘要： 目的 探讨急性淋巴细胞白血病(ALL)异基因造血干细胞移植(allo-HSCT)后移植物抗宿主病(GVHD)的发生率,对预后的影响及其危险因素。 方法 收集2010年10月1日至2018年10月1日山东省立医院血液内科接受allo-HSCT的ALL患者57例,统计原发病基本情况、造血干细胞移植情况、移植物抗宿主病、复发生存等情况,分析移植物抗宿主病的发生率、严重程度以及危险因素。 结果 人类白细胞抗原(HLA)不全相合移植37例,HLA全相合移植20例,2例非血缘全相合移植。供受者血型相合24例,血型不相合33例;同性别移植30例,非同性别移植27例。巨核系中位植入时间13 d(9~47 d),粒系中位植入时间12 d(6~20 d)。急性移植物抗宿主病(aGVHD)累积发生率53.4%,其中Ⅰ~Ⅱ度为42.8%,Ⅲ~Ⅳ度为10.8%。慢性移植物抗宿主病(cGVHD)累积发生率20.3%,其中广泛型cGVHD为5.3%,局限型cGVHD为15.1%。生存分析显示Ⅲ~Ⅳ度aGVHD患者3年生存(OS)率、无白血病生存(LFS)率较无aGVHD及Ⅰ~Ⅱ度aGVHD患者减低(20% vs 69.8%、66.7%, χ2=17.243,P<0.001; 20% vs 60.8%、71%, χ2=9.463,P=0.009),且复发率(RR)及非复发死亡(NRM)升高(60% vs 33.7%、23.9%, χ2=1.788,P=0.409;50% vs 0.71%、0.59%, χ2=21.344,P<0.001)。cGVHD较无cGVHD患者3年OS、LFS减低,差异无统计学意义(44.4% vs 67.6%, χ2=0.142,P=0.706; 50% vs 62.4%, χ2=0.236,P=0.627)。多因素分析显示,HLA配型不合为aGVHD发生的独立危险因素,HLA不全相合较HLA全相合移植aGVHD发生率增加。供受者性别不同为cGVHD的边缘性独立影响因素,非同性别移植较同性别移植cGVHD发生率增加。 结论 GVHD是ALL患者行allo-HSCT的重要并发症,Ⅲ~Ⅳ度aGVHD预后不良,HLA配型不合为发生aGVHD的独立危险因素。

关键词: 急性淋巴细胞白血病, 异基因造血干细胞移植, 移植物抗宿主病, 供受者性别, 人类白细胞抗原

Abstract: Objective To explore the incidence and risk factors of graft-versus-host disease(GVHD)secondary to allogeneic hematopoietic stem cell transplantation(allo-HSCT)in patients with acute lymphoblastic leukemia(ALL). Methods The clinical data of 57 ALL patients who received allo-HSCT in our hospital during Oct. 2010 and Oct. 2018 山 东 大 学 学 报 (医 学 版)57卷7期 -孙菲菲,等.57例急性淋巴细胞白血病异基因造血干细胞移植后抗宿主病的发生及影响因素分析 \=- were retrospectively analyzed. The information primary diseases, HSCT, overall survival(OS), leukemia-free survival(LFS), relapse rate(RR)and non-relapse mortality(NRM)was collected. The incidence, severity and risk factors of GVHD were analyzed. Results The donors were human leukocyte antigen(HLA)-allele mismatched for 37 cases, and matched for 20 cases(2 of which were unrelated). The donors for 24 cases had the identical blood type as the recipients, while donors for 37 cases had incompatible blood type. The donors for 30 cases were the same gender as the recipients, while donors for 27 cases were different gender. Median day of neutrophil and platelet engraftment was 12 d(range: 6-20 d)and 13 d(range: 9-47 d), respectively. Accumulative incidence of acute GVHD(aGVHD)was 53.4%(grade Ⅰ-Ⅱ: 42.8%; grade Ⅲ-Ⅳ: 10.8%). The cumulative incidence of chronic GVHD(cGVHD)was 20.3%, of which 5.3% was extensive and 15.1% was limited. Survival analysis showed that the 3-year OS and LFS of patients with grade Ⅲ-Ⅳ aGVHD were significantly lower than those without or with grade Ⅰ-Ⅱ aGVHD(20% vs 69.8%, 66.7%, χ2=17.243, P<0.001; 20% vs 60.8%, 71%, χ2=9.463, P=0.009), with RR and NRM increased(60% vs 33.7%, 23.9%, χ2=1.788, P=0.409; 50% vs 0.71%, 0.59%, χ2=21.344, P<0.001). The 3-year OS and LFS of patients with cGVHD were lower than those without cGVHD by no significant difference(44.4% vs 67.6%, χ2=0.142, P=0.706; 50% vs 62.4%, χ2=0.236, P=0.627). Multivariate analysis showed that HLA mismatch was a significantly independent risk factor for aGVHD. Gender difference between donors and recipients was an marginally significant independent factor of cGVHD. Conclusion GVHD is an important complication of allo-HSCT in ALL patients. Patients with grade Ⅲ-Ⅳ aGVHD have poor prognosis. HLA mismatch is an independent risk factor for aGVHD.

Key words: Acute lymphoblastic leukemia, Allogeneic hematopoietic stem cell transplantation, Graft-versus-host disease, Gender of donors and recipients, Human leukocyte antigen

中图分类号: 

  • R733.71
[1] Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update[J]. Blood Cancer J, 2017, 7(6): 577.
[2] Speziali C, Paulson K, Seftel M. Hematopoietic cell transplantation for acute lymphoblastic leukemia in adults[J]. Curr Hematol Malig Rep, 2016, 11(3): 175-184.
[3] El Fakih R, Ahmed S, Alfraih F, et al. Hematopoietic cell transplantation for acute lymphoblastic leukemia in adult patients [J]. Hematol Oncol Stem Cell Ther, 2017, 10(4): 252-258.
[4] Khaled SK, Thomas SH, Forman SJ. Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults [J]. Curr Opin Oncol, 2012, 24(2): 182-190.
[5] Ferrara JLM, Chaudhry MS. GVHD: biology matters [J]. Blood Adv, 2018, 2(22): 3411-3417.
[6] Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading [J]. Bone Marrow Transplant, 1995, 15(6): 825-828.
[7] Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors [J]. Transplantation, 1974, 18(4): 295-304.
[8] Goyal RK, Goyal M, Sankaranarayan K. Grading acute graft-versus-host disease: time to reconsider [J]. Pediatr Transplant, 2015, 19(3): 252-254.
[9] Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. the 2014 Clinical Trial Design Working Group report [J]. Biol Blood Marrow Transplant, 2015, 21(3): 389-401.
[10] Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response Criteria Working Group report [J]. Biol Blood Marrow Transplant, 2006, 12(3): 252-266.
[11] Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma [J]. J Clin Oncol, 2007, 25(5): 579-586.
[12] Jamil MO, Mineishi S. State-of-the-art acute and chronic GVHD treatment [J]. Int J Hematol, 2015, 101(5): 452-466.
[13] Teshima T, Reddy P, Zeiser R. Acute graft-versus-host disease: novel biological insights [J]. Biol Blood Marrow Transplant, 2016, 22(1): 11-16.
[14] Zhang L, Chu J, Yu J, et al. Cellular and molecular mechanisms in graft-versus-host disease [J]. J Leukoc Biol, 2016, 99(2): 279-287.
[15] Zheng CC, Zhu XY, Tang BL, et al. Clinical separation of cGvHD and GvL and better GvHD-free/relapse-free survival(GRFS)after unrelated cord blood transplantation for AML [J]. Bone Marrow Transplant, 2017, 52(1): 88-94.
[16] Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease [J]. Lancet, 2009, 373(9674): 1550-1561.
[17] Nassereddine S, Rafei H, Elbahesh E, et al. Acute graft versus host disease: a comprehensive review [J]. Anticancer Res, 2017, 37(4): 1547-1555.
[18] Styczynski J, Tridello G, Gil L, et al. Impact of donor Epstein-Barr virus serostatus on the incidence of graft-versus-host disease in patients with acute leukemia after hematopoietic stem-cell transplantation: a study from the acute leukemia and infectious diseases working parties of the European Society for Blood and Marrow Transplantation [J]. J Clin Oncol, 2016, 34(19): 2212-2220.
[19] Li HH, Li F, Gao CJ, et al. Similar incidence of severe acute GVHD and less severe chronic GVHD in PBSCT from unmanipulated, haploidentical donors compared with that from matched sibling donors for patients with haematological malignancies [J]. Br J Haematol, 2017, 176(1): 92-100.
[20] 黎美章, 章卫平, 王健民, 等. 移植物抗宿主病对白血病异基因外周血干细胞移植预后的影响[J]. 中华血液学杂志, 2014, 35(5): 428-433. LI Meizhang, ZHANG Weiping, WANG Jianmin, et al. Impact of graft versus host disease on outcome of allogeneic peripherial blood stem cell transplantation for leukemia [J]. Chinese Journal of Hematology, 2014, 35(5): 428-433.
[21] Shokouhi S, Bray S, Bakhtiyari S, et al. Effects of aGVHD and cGVHD on survival rate in patients with acute myeloid leukemia after allogeneic stem cell transplantation [J]. Int J Hematol Oncol Stem Cell Res, 2015, 9(3): 112-121.
[22] Yu S, Fan Q, Sun J, et al. Haploidentical transplantation without in vitro T-cell depletion results in outcomes equivalent to those of contemporaneous matched sibling and unrelated donor transplantation for acute leukemia [J]. Medicine(Baltimore), 2016, 95(11): 2973.
[23] Liu HL, Sun ZM, Geng LQ, et al. Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies [J]. Bone Marrow Transplant, 2014, 49(8): 1063-1069.
[24] 常英军. 我如何选择异基因造血干细胞移植供者[J]. 中华血液学杂志, 2016, 37(8): 643-649. CHANG Yingjun. How I choose the best donor in allogeneic hematopoietic stem cell transplantation settings [J]. Chinese Journal of Hematology, 2016, 37(8): 643-649.
[25] 李晓红, 高春记, 达万明, 等. CsA,MTX,MMF联合ATG预防非亲缘供者外周血造血干细胞移植后GVHD的疗效观察[J]. 中国实验血液学杂志, 2010, 18(2): 458-462. LI Xiaohong, GAO Chunji, DA Wanming, et al. Prophylactic effect of CsA, MTX, MMF combined with ATG on GVHD in patients underwent unrelated peripheral blood hematopoietic stem cell transplantation [J]. Journal of Experimental Hematology, 2010, 18(2): 458-462.
[26] Arora M, Klein JP, Weisdorf DJ, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis [J]. Blood, 2011, 117(24): 6714-6720.
[27] 谭亮, 李艳萍, 邓文佳. 移植物抗宿主病的发病机制及预防[J]. 解剖学研究, 2013, 35(1): 61-64.
[28] 王飞雁, 高春记. 慢性移植物抗宿主病的治疗进展[J]. 中国实验血液学杂志, 2017, 25(1): 286-290.
[29] 于迪, 韩雅慧, 扈臣媛, 等. 异基因造血干细胞移植后慢性肝脏移植物抗宿主病的危险因素及预后分析[J]. 中国实验血液学杂志, 2018, 26(4): 1174-1179. YU Di, HAN Yahui, HU Chenyuan, et al. Risk factors and prognosis of hepatic cGVHD after allogeneic hematopoietic stem cell transplantation [J]. Journal of Experimental Hematology, 2018, 26(4): 1174-1179.
[1] 孙丽娜,杜晓晓,张红娟,孟金来. 人类白细胞抗原G调控蜕膜自然杀伤细胞促进滋养细胞侵袭[J]. 山东大学学报 (医学版), 2022, 60(6): 41-45.
[2] 李雪,李栋,时庆,周盼盼,鞠秀丽. Helios在儿童急性淋巴细胞性白血病调节性T细胞中的表达及功能[J]. 山东大学学报（医学版）, 2017, 55(4): 76-81.
[3] 王遥,崔国英,王飞,李长忠. 人类白细胞抗原-E在宫颈癌中的表达及意义[J]. 山东大学学报（医学版）, 2016, 54(9): 59-63.
[4] 丁娟, 郑桂喜, 杜鲁涛, 尹作花, 张建, 王传新. 外周血sHLA-G与PGR、GPR联合检测在胃癌诊断中的效能评估[J]. 山东大学学报（医学版）, 2015, 53(11): 59-63.
[5] 孙元欣1, 秦雪梅1, 刘希民2, 王立志2, 刘传方1, 刘璐1. 异基因造血干细胞移植后aGVHD与调节性T细胞、IL-35的相关性[J]. 山东大学学报(医学版), 2013, 51(3): 89-94.
[6] 杜鲁涛1，王传新1，肖晓燕2，郑妮1，张欣1，张旭华3，王丽丽1，王顺1，董召刚1. 血浆可溶性sHLA-G检测对胃癌早期诊断的意义[J]. 山东大学学报(医学版), 2011, 49(6): 125-129.
[7] 郑妮1，王传新1，邓小梅2，张建1，阚士峰1，张欣1，李伟1，杜鲁涛1. HLA-G在宫颈癌组织中的表达及临床意义[J]. 山东大学学报(医学版), 2010, 48(2): 128-130.
[8] . 人类白细胞抗原G在卵巢恶性肿瘤组织中的表达[J]. 山东大学学报(医学版), 2009, 47(7): 99-102.
[9] 李海英,蒋雪梅,陈士俊 . 慢性乙型肝炎外周血自然杀伤细胞的变化及其与HLA-Cw基因型的关系[J]. 山东大学学报(医学版), 2008, 46(7): 697-700.
[10] 成玉,薛付忠,季晓康,胡平,邵琦,张桂琴 . 基于地理信息系统的中国人群HLA-A、B位点的空间遗传结构[J]. 山东大学学报(医学版), 2008, 46(5): 542-546.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发